BRPI0513101A - forma unitária de dosagem para administração bucal, uso da forma unitária de dosagem e método para preparar a forma unitária de dosagem - Google Patents

forma unitária de dosagem para administração bucal, uso da forma unitária de dosagem e método para preparar a forma unitária de dosagem

Info

Publication number
BRPI0513101A
BRPI0513101A BRPI0513101-4A BRPI0513101A BRPI0513101A BR PI0513101 A BRPI0513101 A BR PI0513101A BR PI0513101 A BRPI0513101 A BR PI0513101A BR PI0513101 A BRPI0513101 A BR PI0513101A
Authority
BR
Brazil
Prior art keywords
dosage unit
unit form
pyy
preparing
composition
Prior art date
Application number
BRPI0513101-4A
Other languages
English (en)
Inventor
Steven Dinh
Huaizhen Wang
Maria Isabel Gomez-Orellana
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of BRPI0513101A publication Critical patent/BRPI0513101A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

FORMA UNITáRIA DE DOSAGEM PARA ADMINISTRAçãO BUCAL, USO DA FORMA UNITáRIA DE DOSAGEM E MéTODO PARA PREPARAR A FORMA UNITáRIA DE DOSAGEM - presente invenção provê uma composição (ex: uma composição farmacêutica) compreendendo pelo menos um composto agente de liberação e pelo menos um de peptídeo YY (PYY) e um agonista de PYY. Preferivelmente, a composição inclui uma quantidade terapeuticamente eficaz de peptídeo YY ou do agonista de PYY e o composto agente de liberação. A composição da presente invenção facilita a liberação de PYY, um agonista de PYY, ou uma mistura dos mesmos, e aumenta sua biodisponibilidade em comparação com a administração sem o composto agente de liberação. O PPY e os agonistas de PYY possuem atividade como agentes para reduzir a disponibilidade de nutrientes, inclusive a redução de ingestão de alimentos.
BRPI0513101-4A 2004-07-12 2005-07-12 forma unitária de dosagem para administração bucal, uso da forma unitária de dosagem e método para preparar a forma unitária de dosagem BRPI0513101A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58775104P 2004-07-12 2004-07-12
PCT/US2005/024599 WO2006017251A2 (en) 2004-07-12 2005-07-12 Compositions for delivering peptide yy and pyy agonists

Publications (1)

Publication Number Publication Date
BRPI0513101A true BRPI0513101A (pt) 2008-04-29

Family

ID=35839770

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513101-4A BRPI0513101A (pt) 2004-07-12 2005-07-12 forma unitária de dosagem para administração bucal, uso da forma unitária de dosagem e método para preparar a forma unitária de dosagem

Country Status (11)

Country Link
US (2) US9399054B2 (pt)
EP (1) EP1791553B1 (pt)
JP (1) JP5749879B2 (pt)
CN (2) CN105708787A (pt)
AU (1) AU2005271878B2 (pt)
BR (1) BRPI0513101A (pt)
CA (1) CA2573512C (pt)
MX (1) MX2007000510A (pt)
NZ (1) NZ552558A (pt)
WO (1) WO2006017251A2 (pt)
ZA (1) ZA200701044B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010090876A2 (en) * 2009-01-21 2010-08-12 University Of Florida Research Foundation, Inc. Satiation peptide administration
AU2010279575B2 (en) 2009-08-03 2016-05-05 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
US8562589B2 (en) 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
CA2993215C (en) * 2015-07-02 2023-10-31 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
SG11201903697WA (en) 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
US12297457B2 (en) 2017-10-10 2025-05-13 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
KR20200131812A (ko) * 2018-01-09 2020-11-24 길라 테라퓨틱스, 인코포레이티드 대사 질병을 치료하기 위한 조성물 및 방법
MX2020007410A (es) * 2018-01-23 2020-11-09 Gila Therapeutics Inc Formulaciones, composiciones y métodos farmacéuticos de péptido yy.
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN111995536A (zh) * 2018-06-25 2020-11-27 上海龙灯环保科技有限公司 季戊四醇四((n,n-二(2-氨基乙基))-3-氨基丙酸酯)的制备方法
US12421500B2 (en) 2018-07-26 2025-09-23 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
JP2021535753A (ja) 2018-09-12 2021-12-23 チルドレンズ ホスピタル メディカル センター 造血幹細胞およびその派生体の生成のためのオルガノイド組成物
CA3126358A1 (en) * 2019-01-14 2020-07-23 Children's Hospital Medical Center Compositions and methods for treatment of a malabsorptive disorder
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
CA3141814A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CN114174494A (zh) 2019-05-31 2022-03-11 儿童医院医学中心 产生和扩增造血干细胞的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6313088B1 (en) * 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
CA2319680C (en) 1997-02-07 2010-04-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2000048589A1 (en) * 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
NZ534409A (en) * 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
HK1048801B (en) 1999-11-05 2009-08-28 Emisphere Technologies, Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
JP4799794B2 (ja) * 2000-03-21 2011-10-26 エミスフェアー・テクノロジーズ・インク ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。
AU2002230843B8 (en) * 2000-12-14 2007-05-17 Amylin Pharmaceuticals, Llc Peptide YY and peptide YY agonists for treatment of metabolic disorders
NZ527157A (en) * 2001-03-01 2005-04-29 Emisphere Tech Inc Compositions for delivering bisphosphonates
PL205971B1 (pl) * 2001-09-24 2010-06-30 Imp Innovations Ltd Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
CA2510199A1 (en) * 2002-12-17 2004-07-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
NZ543274A (en) * 2003-05-14 2007-12-21 Emisphere Tech Inc Compositions for delivering peptide YY and PYY agonists

Also Published As

Publication number Publication date
US20160296599A1 (en) 2016-10-13
CN105708787A (zh) 2016-06-29
EP1791553A4 (en) 2012-09-05
CN101443028A (zh) 2009-05-27
CA2573512C (en) 2014-09-23
EP1791553B1 (en) 2013-10-23
WO2006017251A3 (en) 2008-11-13
EP1791553A2 (en) 2007-06-06
NZ552558A (en) 2009-11-27
MX2007000510A (es) 2007-03-29
AU2005271878B2 (en) 2010-02-18
HK1107524A1 (en) 2008-04-11
JP2008505973A (ja) 2008-02-28
JP5749879B2 (ja) 2015-07-15
US20110183898A1 (en) 2011-07-28
WO2006017251A2 (en) 2006-02-16
ZA200701044B (en) 2008-12-31
US9399054B2 (en) 2016-07-26
AU2005271878A1 (en) 2006-02-16
CA2573512A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
BRPI0411165A (pt) composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
WO2006017251A3 (en) Compositions for delivering peptide yy and pyy agonists
IL194883A0 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol
CL2022000033A1 (es) Composición farmacéutica para suministro nasal
MX2010008802A (es) Formulacion liquida de la fsh.
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
AU2007247480A8 (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
BRPI0906866A2 (pt) métodos e composições para administração oral de agentes terapêutico de proteína e peptídeo
BR0314450A (pt) Sais de ácido borÈnico com adição de uma base farmaceuticamente aceitável, formulação farmacêutica, e uso dos referidos sais para preparar uma formulação farmacêutica
UA99914C2 (ru) Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
BRPI0510449A (pt) uso de formulações de meloxicam em medicina veterinária
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
MXPA05009629A (es) Composiciones que contienen trospio.
BRPI0614197B8 (pt) composição farmaceuticamente eficaz em uma forma farmacêutica para administração peroral contendo pelo menos um dos ingredientes ativos indometacina e acemetacina, formas de administração, e, uso da composição
BRPI0918593A2 (pt) composição farmacêutica para uso no tratamento de infecções transmitidas sexualmente
WO2007011958A3 (en) Intraoral dosage forms of glucagon
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
WO2007017875A3 (en) Drug delivery system for topical administration
BR0315231A (pt) Compostos com base em glicose com afinidade para p-seletina
BR112021026561A2 (pt) Uso de uma composição farmacêutica na fabricação de um medicamento para a prevenção ou tratamento de doença hepática
BR0312283A (pt) Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf
WO2009076983A3 (en) Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL